Company Overview and News
Greetings and welcome to the TG Therapeutics’ Third Quarter 2017 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. (18-2)
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (418-2)
The biotech sector will try to overcome some late weakness last week as trading opens today. (277-3)
If you want a Stock Review on CYCC, TGTX, VCEL, or AKAO then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. This morning's attention is redirected to the Biotech industry, which focuses on novel drug development and clinical research aimed at treating diseases and medical conditions. Biotech companies are almost always unprofitable (some suggest that the distinction between "biotech" and "pharmaceutical company" lies in profitability), and many have no real revenue at all. (267-13)
* TG Therapeutics -first patient been dosed in phase 1 clinical trial evaluating safety & tolerability of proprietary fully-human anti-PD-l1 monoclonal antibody Source text for Eikon: Further company coverage: (18-1)
Welcome to another edition of "3 Thing In Biotech You Should Learn Today," the daily digest dedicated to helping you keep up with the latest findings and news from the world of pharmaceuticals and biotechnology.
Last week, two significant volatility streaks for the S&P 500 were ended, but the streak of at least one portfolio stock gaining more than 10% continues past 7 straight weeks. (0-2)
Greetings, and welcome to the TG Therapeutics Second Quarter Earnings Conference Call. At this time, all participants are in a listen-only-mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest highlighting recent news from the biotechnology and pharmaceutical industries. The goal here is to help forward your due diligence and identify new potential opportunities.
The Biotechnology sector remains one of the top performing sectors this year with the benchmark Nasdaq Biotechnology Index, as represented by ETF (IBB), gaining 17% in the first-half. The index though still remains ~29% down from its all-time high achieved in mid-2015. In comparison, the S&P 500 (SPY) was up 8%, and the Nasdaq Composite (QQQ) up 14%, in the first-half.
Today we revisit two previously positively profiled small cap oncology plays that have been in rally mode recently. (0-2)
Monetary policy became more aggressive last month with the announcement of the balance sheet normalization program.
The financial position of the company and the "second" drug in the pipeline are overlooked aspects of MEI Pharma. (0-1)
Stock Research Report
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, TG Therapeutics is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 also in clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 (interleukin-1 receptor-associated kinase 4) inhibitors, BET (Bromodomain an...
2017-10-28 - Wilton
2017-10-25 - Wilton
2017-10-10 - Wilton
2017-10-09 - Wilton
2017-08-25 - Wilton